A proof-of-concept trial assessing ARGX-117 in prevention of delayed graft function and/or allograft failure after kidney transplantation
Latest Information Update: 17 Jan 2025
At a glance
- Drugs Empasiprubart (Primary)
- Indications Delayed graft function
- Focus Proof of concept; Therapeutic Use
- Sponsors argenx
Most Recent Events
- 13 Jan 2025 According to Argenx media release, topline results expected in DGF in second half of 2025.
- 02 Mar 2023 According to Argenx media release, this trial is expected to initiate in the second half of 2023.
- 27 Oct 2022 According to Argenx media release, this trial is expected to initiate following regulatory discussions.